Entyvio 300 MG vials
Ended Awarded
- Contract number
- SPE2DR26FKFT8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $29,284
Award facts
- Contract value 100% obligated
- $29,284.08 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $29,284.08 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Entyvio 300 mg vials. This delivery order, issued on November 13, 2025, with an ultimate completion date of November 14, 2025, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group serves as a critical supplier within the Department of Defense's pharmaceutical supply chain, specializing in distributing a comprehensive range of pharmaceuticals and medical consumables to federal agencies.
This delivery order is issued under DMS Pharmaceutical Group's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) Indefinite Delivery Contract (SPE2DR), which was awarded on November 13, 2025, with a ceiling value of $499,999,999 and an ultimate completion date of December 31, 2036. The parent contract, structured as a 30-month base period with three 30-month option periods, positions DMS Pharmaceutical Group as one of multiple regional prime vendor contractors under the Defense Logistics Agency's broader $30.3 billion PPV-G GEN V acquisition strategy. The contract authorizes DLA to issue firm fixed-price delivery orders for branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the recurring medical supply needs of Department of Defense healthcare facilities worldwide.
Quick answers
Who was awarded contract SPE2DR26FKFT8?
SPE2DR26FKFT8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 13, 2025.
How much is contract SPE2DR26FKFT8 worth?
The government has obligated $29,284 on SPE2DR26FKFT8.
Is contract SPE2DR26FKFT8 an order under another contract?
Yes. SPE2DR26FKFT8 is a delivery order under SPE2DR25D9362, an indefinite delivery contract.
Was contract SPE2DR26FKFT8 competed?
The extent of competition for SPE2DR26FKFT8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award